ReviewNature reviews. Neuroscience2020
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders.
Review in Nature reviews. Neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 244 papers, 12 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
244 citing papers in PubMed, 12 syntheses or guidelines pooled it.
- Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.Acta neuropsychiatrica · 2025Pooled it
- Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.Eating and weight disorders : EWD · 2025Pooled it
- Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- What fMRI studies say about the nature of the psychedelic effect: a scoping review.Frontiers in neuroscience · 2025Pooled it
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2024Pooled it
- The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.CNS drugs · 2023Pooled it
- Dose-response relationships of LSD-induced subjective experiences in humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Pooled it
- Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.CNS drugs · 2022Pooled it
- Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026Trial
- Acute effects of selective serotonin reuptake inhibitors on cerebral glucose metabolism and blood flow.Translational psychiatry · 2026Trial
- Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Neural mechanisms of psychedelic visual imagery.Molecular psychiatry · 2025Trial
- Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.Molecular psychiatry · 2025Trial
- Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial.Journal of vision · 2024Trial
- Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.Translational psychiatry · 2023Trial
184 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renewed interest in the use of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. After a hiatus of about 50 years, state-of-the art studies have recently begun to close important knowledge gaps by elucidating the mechanisms of action of psychedelics with regard to their effects on receptor subsystems, systems-level brain activity and connectivity, and cognitive and emotional processing. In addition, functional studies have shown that changes in self-experience, emotional processing and social cognition may contribute to the potential therapeutic effects of psychedelics. These discoveries provide a scientific road map for the investigation and application of psychedelic substances in psychiatry.
Indexed as
Identifiers
32929261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.